Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.

ABSTRACT:

Background

For patients diagnosed with triple-negative breast cancer (TNBC), residual disease (RD) after neoadjuvant chemotherapy (NAC) is associated with increased rates of recurrence and poor prognosis. Adjuvant therapy with capecitabine is considered standard management for TNBC-RD based on the CREATE-X study, although real-world data are limited. Real-world utilization of adjuvant capecitabine for patients with TNBC-RD and the association of capecitabine with survival outcomes remains largely unknown.

Patients and methods

We evaluated survival outcomes in patients with stage I-III TNBC (including estrogen and progesterone receptor <10%) who received NAC and underwent breast surgery between January 2016 and June 2019 at three comprehensive cancer centers. Treatment in the

SUBMITTER: Strahan A 

PROVIDER: S-EPMC12414891 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature